FDA clears handheld ultrasound from Rivanna

Rivanna Medical has announced that Accuro, the company’s handheld ultrasound device, has received FDA 510(k) clearance and can now be marketed in the U.S.

Accuro is a smart phone-sized, untethered ultrasound platform designed specifically to guide spinal anesthesia with automated 3D navigation technology, according to Rivanna. It can also perform ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies.

“The Accuro platform, which is based on automated superior imaging technology, has an addressable $1+ billion U.S. market today,” said John A. Williams, president and CEO of Rivanna, in a press release. “Because of the considerable unmet clinical need for automated image guidance in general, and in the spinal anesthesia market especially, we are looking forward to launching Accuro at the upcoming annual scientific meeting of the American Society of Anesthesiologist (ASA) in San Diego in just three months.”

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease. 

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care.